Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...

ASX companies such as LTR Pharma are finding smarter ways to stretch the value of existing assets and launch into broader ...

Wake Tech is excited to launch a distinctive apprenticeship program in partnership with life sciences leaders CSL Seqirus, ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Though nerves abound for funders and founders in the industry, money continues to flow into startups, sometimes in ...

After a tough few weeks for Sarepta Therapeutics Inc., the EMA dealt another blow on July 25, announcing it will not be ...

South Korea’s biopharmaceutical sector has seen a surge in innovator drug licensing agreements, reaching a total deal value of $7.86bn in 2025 year-to-date (YTD), at a 113% increase from 2024, ...

Haroon Akhtar emphasised that the establishment of a pharmaceutical joint venture between Pakistan and Russia marks a ...